Every material Form 8-K agilon health, inc. has filed with the SEC since July 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
agilon health reported third quarter 2026 revenue of $1.52 billion, up 6% from a year earlier, and net income of $35 million compared with a net loss of $110 million in the third quarter of 2025. The company raised its full-year 2026 Adjusted EBITDA guidance to $145 million to $155 million from $75 million to $95 million, but total members on its platform fell 8% year over year to 566,000.
Third quarter revenue was $1.52 billion, up 6% from $1.44 billion in the third quarter of 2025.
Net income was $35 million, or $1.97 per diluted share, versus a net loss of $110 million, or $6.65 per share, a year earlier.
Full-year 2026 Adjusted EBITDA guidance was raised to $145 million to $155 million from $75 million to $95 million.
Total members live on the platform were 566,000 as of September 30, 2026, down from 618,000.
agilon health reported second quarter 2026 total revenue of $1.49 billion, up 7% from a year earlier, and net income of $18 million versus a net loss of $104 million in the second quarter of 2025. The company raised its full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA, though total members on its platform fell 10% to 549,000.
Q2 2026 total revenue was $1.49 billion, up 7% from $1.39 billion; net income was $18 million versus a net loss of $104 million in Q2 2025.
Total members on the platform fell 10% year over year to 549,000 as of June 30, 2026.
Full-year 2026 guidance: total revenues $5.775 billion to $5.860 billion (previously $5.680 billion to $5.805 billion); medical margin $465 million to $505 million (previously $350 million to $400 million); Adjusted EBITDA $75 million to $9
Third quarter 2026 guidance: total revenues $1.445 billion to $1.475 billion; Adjusted EBITDA negative $5 million to positive $5 million.
agilon health notified Chief Technology Officer Girish Venkatachaliah on July 17, 2026 that his employment will end August 1, 2026. He will provide transition consulting through December 31, 2026, and his severance includes cash and continued equity vesting through April 30, 2027.
Separation date: August 1, 2026; notice given July 17, 2026
Cash severance totaling $766,063, paid in installments over twelve months
Equity awards, including the 2025 transformation award, keep vesting through April 30, 2027
Consulting agreement through December 31, 2026, with no pay beyond continued equity vesting
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every agilon health, inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →